Maximal androgen blockade for advanced prostate cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Maximal androgen blockade (MAB) combines castration with anti-androgens for advanced prostate cancer.
• Anti-androgens function as androgen-receptor antagonists, inhibiting both ligand-dependent and -independent activation pathways.
• Understanding these mechanisms is crucial for optimizing prostate cancer treatment.

Purpose of the Study:

• To review the clinical evidence for MAB in advanced prostate cancer.
• To compare the efficacy of different anti-androgens within MAB regimens.
• To identify optimal treatment strategies for high-risk prostate cancer patients.

Main Methods:

• Review of approximately 30 clinical trials evaluating MAB versus monotherapy over 25 years.
• Analysis of meta-analyses assessing survival benefits of MAB.
• Examination of preclinical data and randomized trials comparing bicalutamide-based MAB with castration alone.

Main Results:

• Meta-analyses indicate an 8% mortality reduction at 5 years with MAB (flutamide/nilutamide) compared to monotherapy.
• Preclinical data and early trial results suggest bicalutamide may offer superior efficacy.
• Further data from ongoing trials are needed to confirm bicalutamide's advantage.

Conclusions:

• MAB provides a modest survival benefit in advanced prostate cancer.
• Bicalutamide-based MAB warrants consideration for high-risk patients due to potential enhanced efficacy.
• Continued research is essential to refine MAB strategies and anti-androgen selection.